Korean Dong-A In Talks With Warner Chilcott For Additional Indications For ED Drug Zydena
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Dong-A Pharmaceutical says its U.S. partner Warner Chilcott is seeking an expanded indication of lower urinary track symptoms for its erectile dysfunction drug Zydena (udenafil)
You may also be interested in...
Struggling From Price Cuts, Korea’s Dong-A Looks To Change Course
Korea’s top pharma company saw flat sales and a drop in profits in the third quarter, showing the impact of industry-wide price cuts. GSK holds a 10% stake in Dong-A.
Pfizer's Viagra Challenged As Korea's JW Choongwae Launches ED Product In Korea
SEOUL - South Korea's JW Choongwae Pharmaceutical Corp. launched its new erectile dysfunction product Zepeed (avanafil) in Korea Oct. 19, ahead of approval in the U.S
Pfizer's Viagra Challenged As Korea's JW Choongwae Launches ED Product In Korea
SEOUL - South Korea's JW Choongwae Pharmaceutical Corp. launched its new erectile dysfunction product Zepeed (avanafil) in Korea Oct. 19, ahead of approval in the U.S